Chinese drug regulators granted ApicHope Pharmaceutical (SHE:300723) subsidiary Guangzhou ApicHope Pharmaceutical a drug registration certificate for its levofloxacin oral solution, according to a Friday filing with the Shenzhen bourse.
The antibiotic is indicated for bacterial infections such as hospital- and community-acquired pneumonia, bacterial sinusitis, bacterial exacerbation of chronic bronchitis, skin infections, uncomplicated urinary tract infections, pyelonephritis, and inhalation anthrax, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments